![Henning Scheich](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Henning Scheich
Gründer bei Leibniz Institute for Neurobiology
Aktive Positionen von Henning Scheich
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Leibniz Institute for Neurobiology | Gründer | 31.08.2009 | - |
Corporate Officer/Principal | 31.08.2009 | - | |
Germany Ministry of Education & Research | Corporate Officer/Principal | 31.08.2009 | - |
Karriereverlauf von Henning Scheich
Ehemalige bekannte Positionen von Henning Scheich
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
KeyNeurotek Pharmaceuticals AG
![]() KeyNeurotek Pharmaceuticals AG Pharmaceuticals: OtherHealth Technology KeyNeurotek Pharmaceuticals AG is a biopharmaceutical company focused on the development of innovative small molecule drugs for the treatment of neuronal and autoimmune diseases. KeyNeurotek’s drug portfolio covers the entire drug development chain from research stage to advanced clinical development. At present, two compounds are in clinical development, KN38-7271 and KN203, both addressing significant markets such as traumatic brain injury, TBI, stroke, and urinary incontinence/overactive bladder. The company’s product development is based on its proprietary technology platform, which has been specifically tailored to diseases of the central nervous system, TELOMICS. KeyNeurotek was founded by Dr Frank Striggow, Frank Baumgart, Prof Dr Klaus G. Reymann and Prof Dr Henning Scheich in May 2000. The company is located in Magdeburg, Germany. | Direktor/Vorstandsmitglied | 31.08.2009 | 03.08.2011 |
Gründer | 31.08.2009 | 03.08.2011 |
Statistik
International
Deutschland | 4 |
Operativ
Corporate Officer/Principal | 2 |
Founder | 2 |
Director/Board Member | 1 |
Sektoral
Health Technology | 2 |
Government | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 3 |
---|---|
KeyNeurotek Pharmaceuticals AG
![]() KeyNeurotek Pharmaceuticals AG Pharmaceuticals: OtherHealth Technology KeyNeurotek Pharmaceuticals AG is a biopharmaceutical company focused on the development of innovative small molecule drugs for the treatment of neuronal and autoimmune diseases. KeyNeurotek’s drug portfolio covers the entire drug development chain from research stage to advanced clinical development. At present, two compounds are in clinical development, KN38-7271 and KN203, both addressing significant markets such as traumatic brain injury, TBI, stroke, and urinary incontinence/overactive bladder. The company’s product development is based on its proprietary technology platform, which has been specifically tailored to diseases of the central nervous system, TELOMICS. KeyNeurotek was founded by Dr Frank Striggow, Frank Baumgart, Prof Dr Klaus G. Reymann and Prof Dr Henning Scheich in May 2000. The company is located in Magdeburg, Germany. | Health Technology |
Leibniz Institute for Neurobiology | |
Germany Ministry of Education & Research | Government |
- Börse
- Insiders
- Henning Scheich
- Erfahrung